Effect of age on functional P‐glycoprotein in the blood‐brain barrier measured by use of (R)‐[11C]verapamil and positron emission tomography

P‐glycoprotein (P‐gp) is an efflux transporter responsible for the transport of various drugs across the blood‐brain barrier (BBB). Loss of P‐gp function with age may be one factor in the development and progression of neurodegenerative diseases. The aim of this study was to assess the effect of aging on BBB P‐gp function. Furthermore, the relationship between BBB P‐gp activity and peripheral P‐gp activity in CD3‐positive leukocytes was investigated. Finally, plasma pharmacokinetics of carbon 11–labeled (R)‐verapamil was evaluated.

[1]  D. Greenblatt,et al.  The Effect of Age on P-Glycoprotein Expression and Function in the Fischer-344 Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.

[2]  Stephen M Smith,et al.  Fast robust automated brain extraction , 2002, Human brain mapping.

[3]  Jan Stankiewicz,et al.  Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. , 2003, Pharmacogenetics.

[4]  Stephen M. Smith,et al.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.

[5]  R. Boellaard,et al.  (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. , 2003, Nuclear medicine and biology.

[6]  W Vaalburg,et al.  Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography , 1998, British journal of pharmacology.

[7]  R. Calado,et al.  Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. , 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[8]  Ronald Boellaard,et al.  Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET , 2001, European Journal of Nuclear Medicine.

[9]  Alan C. Evans,et al.  Positron Emission Tomography Partial Volume Correction: Estimation and Algorithms , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  H. Aronen,et al.  [Functional magnetic resonance imaging of the brain]. , 1997, Duodecim; laaketieteellinen aikakauskirja.

[11]  R. Calado,et al.  Age-related changes of P-glycoprotein-mediated rhodamine 123 efflux in normal human bone marrow hematopoietic stem cells , 2003, Leukemia.

[12]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[13]  M. Eichelbaum,et al.  Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. , 2002, Pharmacogenetics.

[14]  K. Frei,et al.  Molecular and cellular permeability control at the blood–brain barrier , 2001, Brain Research Reviews.

[15]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[16]  M. Fromm,et al.  Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. , 2000, The Journal of pharmacology and experimental therapeutics.

[17]  Kazuyoshi Yajima,et al.  Brain FDG PET study of normal aging in Japanese: effect of atrophy correction , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Gert Luurtsema,et al.  Fully automated high yield synthesis of (R)‐ and (S)‐[11C]verapamil for measuring P‐glycoprotein function with positron emission tomography , 2002 .

[19]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Feller,et al.  Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia , 2001, Leukemia.

[21]  E. Benedetti,et al.  An assessment of P-glycoprotein expression and activity in peripheral blood lymphocytes of transplant candidates. , 2005, Transplantation proceedings.

[22]  J. Gorell,et al.  Multiple risk factors for Parkinson's disease , 2004, Journal of the Neurological Sciences.

[23]  Christiane Kunert-Keil,et al.  Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. , 2002, Pharmacogenetics.

[24]  D. Mankoff,et al.  Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.

[25]  C. Baumgartner,et al.  Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans , 2005, Clinical pharmacology and therapeutics.

[26]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[27]  G Brix,et al.  Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Guy Marchal,et al.  Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.

[29]  D. Kroetz,et al.  No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects , 2003, Clinical pharmacology and therapeutics.

[30]  J. Kigawa,et al.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.

[32]  K. Nakayama,et al.  Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. , 2003, Biochemical pharmacology.

[33]  Joost Bart,et al.  Quantitative assessment of P-glycoprotein function in the rat blood–brain barrier by distribution volume of [11C]verapamil measured with PET , 2003, NeuroImage.

[34]  J. Bart,et al.  Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.

[35]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[36]  N. Shaik,et al.  Drug efflux transporters in the CNS. , 2003, Advanced drug delivery reviews.

[37]  Gert Luurtsema,et al.  Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. , 2005, Nuclear medicine and biology.